- ►diabetesjournals.org DJ Drucker - Diabetes care, 2007 - Am Diabetes Assoc Dipeptidyl peptidase (DPP)-4 is a complex enzyme that exists as a
membrane-anchored cell surface peptidase that transmits intracellular signals
via a short intracellular tail and as a second smaller soluble form present ... Cited by 42 - Related articles - BL Direct - All 11 versions
- ►diabetesjournals.org BJ Lamont, DJ Drucker - Diabetes, 2008 - Am Diabetes Assoc RESULTS AND CONCLUSIONS— Mice treated with vehicle alone or DA-GIP exhibited
progressive weight gain, whereas treatment with Ex-4 or DPP-4i prevented weight
gain. Although Ex-4 improved oral glucose tolerance and insulin-to-glucose ... Cited by 17 - Related articles - BL Direct - All 5 versions
- ►endojournals.org AW Herling, S Kilp, R Elvert, G Haschke, W … - Endocrinology, 2008 - Endocrine Soc The CB1 receptor antagonist, rimonabant, affects the endocannabinoid system and
causes a sustained reduction in body weight (BW) despite the transient nature of
the reduction in food intake. Therefore, in a multiple-dose study, female ... Cited by 15 - Related articles - BL Direct - All 4 versions
- ►glp1.eu [PDF] D Russell-Jones - Molecular and cellular endocrinology, 2009 - Elsevier GLP-1 has a number of acute effects on glucose sensing and insulin secretion by
the beta cell, including closure of K ATP channels, shifting membrane potential
and sensitising beta cells to glucose (Holz et al., 1992), reduction of ... Cited by 9 - Related articles - All 4 versions
ES Horton - Endocrine Practice, 2008 - AACE The global prevalence of diabetes has been increasing in recent decades,
reaching near-epidemic proportions. The number of persons with the disease was
estimated at 171 million in the year 2000 and is projected to more than ... Cited by 4 - Related articles - All 7 versions
H Su, M He, H Li, Q Liu, J Wang, Y Wang, W … - PLoS One, 2008 - pubmedcentral.nih.gov C57BL/6J and db/db mice were treated daily with Boc5 for 4 weeks and a range of
pharmacologic parameters, including hemoglobin A1c, intraperitoneal glucose
tolerance, insulin tolerance, fasting insulin and leptin levels, food ... Cited by 3 - Related articles - All 6 versions
SL Samson, EV Gonzalez, V Yechoor, M Bajaj … - Molecular therapy: the journal of the American Society …, 2008 - pubmedcentral.nih.gov Exendin 4 (Ex4) is a glucagon-like peptide-1 receptor (GLP- 1R) agonist which is
available as a short-acting injectable treatment for type 2 diabetes. Our aim
was to characterize the long-term effects of elevated steady-state levels ... Cited by 1 - Related articles - All 5 versions
D TREATMENT - CLEVELAND CLINIC JOURNAL OF MEDICINE, 2008 - ccjm.highwire.org The gliptins, a new class of oral drugs for type 2 diabetes mellitus, lower
blood glucose levels by a novel mechanism: ie, by inhibiting the enzyme
dipeptidyl peptidase 4, thereby increasing the circulating levels of ... Related articles - All 3 versions
MK Piya, AA Tahrani, AH Barnett - Future Prescriber, 2008 - interscience.wiley.com Type 2 diabetes mellitus (T2DM) is a global epidemic with an expected prevalence
of 380 million in 2025 worldwide 1 and over 2.5 million by 2010 in the UK. 2
Diabetes is a progres-sive disease which leads to macro and microvascular ... Related articles
T Vilsbøll - Therapy, 2009 - Future Medicine Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted by the
intestinal mucosa in response to nutrient ingestion. Although GLP-1 has multiple
potentially beneficial effects, it is unsuitable as a therapy in Type 2 ... Related articles - All 3 versions
